Lisata Therapeutics (LSTA)
Lisata Therapeutics on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
29K
Short interest
settlement 2026-10-15
1.0
Days to cover
unchanged vs prior
37.4%
Short share of volume
2026-11-02
18,139
Fails to deliver
settlement 2026-08-24
Thu 5 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in LSTA is 28,797 shares, down 136,156 shares over the last month. Over the last 48 readings it ranged from 7,804 shares (15 January 2026) to 164,953 shares (15 September 2026). At the reported average volume of 151K shares a day that is 1.0 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/lsta" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 28,797 | -26.9% | 151,189 | 1.00 |
| 2026-09-30 | 39,407 | -76.1% | 362,256 | 1.00 |
| 2026-09-15 | 164,953 | +16.3% | 189,466 | 1.00 |
| 2026-08-31 | 141,798 | +57.8% | 844,223 | 1.00 |
| 2026-08-14 | 89,867 | +59.5% | 78,742 | 1.14 |
| 2026-07-31 | 56,341 | -56.6% | 155,428 | 1.00 |
| 2026-07-15 | 129,920 | +23.9% | 46,167 | 2.81 |
| 2026-06-30 | 104,813 | +17.0% | 20,026 | 5.23 |
| 2026-06-15 | 89,589 | -27.9% | 201,155 | 1.00 |
| 2026-05-29 | 124,163 | +32.8% | 220,592 | 1.00 |
| 2026-05-15 | 93,493 | +33.1% | 31,249 | 2.99 |
| 2026-04-30 | 70,246 | +36.0% | 89,540 | 1.00 |
| 2026-04-15 | 51,644 | +204.9% | 100,691 | 1.00 |
| 2026-03-31 | 16,935 | +14.9% | 51,984 | 1.00 |
| 2026-03-13 | 14,741 | -3.7% | 107,459 | 1.00 |
| 2026-02-27 | 15,304 | -49.3% | 47,528 | 1.00 |
| 2026-02-13 | 30,190 | +8.2% | 105,659 | 1.00 |
| 2026-01-30 | 27,898 | +257.5% | 638,622 | 1.00 |
| 2026-01-15 | 7,804 | -16.3% | 44,684 | 1.00 |
| 2025-12-31 | 9,326 | -39.6% | 33,508 | 1.00 |
| 2025-12-15 | 15,440 | -13.9% | 22,401 | 1.00 |
| 2025-11-28 | 17,930 | -16.2% | 24,506 | 1.00 |
| 2025-11-14 | 21,397 | +10.8% | 236,072 | 1.00 |
| 2025-10-31 | 19,308 | -1.3% | 50,586 | 1.00 |
| 2025-10-15 | 19,558 | -48.7% | 53,555 | 1.00 |
| 2025-09-30 | 38,114 | +146.0% | 24,958 | 1.53 |
| 2025-09-15 | 15,493 | +33.4% | 23,238 | 1.00 |
| 2025-08-29 | 11,612 | -26.9% | 21,106 | 1.00 |
| 2025-08-15 | 15,896 | -66.8% | 43,809 | 1.00 |
| 2025-07-31 | 47,895 | +62.1% | 32,494 | 1.47 |
| 2025-07-15 | 29,548 | -3.8% | 72,051 | 1.00 |
| 2025-06-30 | 30,721 | -0.3% | 20,783 | 1.48 |
| 2025-06-13 | 30,815 | +8.6% | 9,216 | 3.34 |
| 2025-05-30 | 28,381 | +20.2% | 18,194 | 1.56 |
| 2025-05-15 | 23,619 | -8.6% | 11,533 | 2.05 |
| 2025-04-30 | 25,851 | -9.4% | 10,687 | 2.42 |
| 2025-04-15 | 28,535 | -15.4% | 16,779 | 1.70 |
| 2025-03-31 | 33,746 | +6.9% | 8,831 | 3.82 |
| 2025-03-14 | 31,564 | -21.3% | 12,019 | 2.63 |
| 2025-02-28 | 40,079 | +50.1% | 22,390 | 1.79 |
| 2025-02-14 | 26,705 | +29.5% | 22,638 | 1.18 |
| 2025-01-31 | 20,627 | -16.7% | 89,905 | 1.00 |
| 2025-01-15 | 24,751 | +50.5% | 87,824 | 1.00 |
| 2024-12-31 | 16,440 | -14.1% | 18,235 | 1.00 |
| 2024-12-13 | 19,128 | +26.8% | 21,473 | 1.00 |
| 2024-11-29 | 15,090 | +59.0% | 19,835 | 1.00 |
| 2024-11-15 | 9,491 | -44.4% | 19,054 | 1.00 |
| 2024-10-31 | 17,064 | -28.3% | 8,979 | 1.90 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of LSTA volume is 37.4%, up 11.9 points over the last five sessions. Over the last 30 readings it ranged from 0.3% (22 October 2026) to 83.4% (25 September 2026). The latest reading is 17.9 points above the 30-session average of 19.5%, on 42K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 16K | 42K | 37.4% | 0 |
| 2026-10-30 | 3K | 31K | 8.3% | 0 |
| 2026-10-29 | 2K | 19K | 9.0% | 0 |
| 2026-10-28 | 8K | 32K | 25.4% | 0 |
| 2026-10-27 | 7 | 20 | 35.0% | 0 |
| 2026-10-26 | 11K | 44K | 25.5% | 0 |
| 2026-10-23 | 9K | 29K | 32.1% | 0 |
| 2026-10-22 | 33 | 13K | 0.3% | 0 |
| 2026-10-21 | 3K | 17K | 15.6% | 0 |
| 2026-10-20 | 12K | 44K | 28.4% | 0 |
| 2026-10-19 | 3K | 44K | 6.8% | 1,896 |
| 2026-10-16 | 7K | 42K | 16.7% | 0 |
| 2026-10-15 | 204 | 13K | 1.6% | 0 |
| 2026-10-14 | 5K | 47K | 9.6% | 0 |
| 2026-10-13 | 28K | 116K | 24.4% | 267 |
| 2026-10-12 | 6K | 96K | 6.8% | 1,025 |
| 2026-10-09 | 24K | 133K | 18.1% | 2,160 |
| 2026-10-08 | 31K | 173K | 17.8% | 0 |
| 2026-10-07 | 994 | 5K | 19.5% | 0 |
| 2026-10-06 | 27K | 88K | 30.5% | 5,828 |
| 2026-10-05 | 812 | 26K | 3.2% | 0 |
| 2026-10-02 | 40 | 854 | 4.7% | 0 |
| 2026-10-01 | 4K | 37K | 11.8% | 0 |
| 2026-09-30 | 2K | 5K | 46.0% | 0 |
| 2026-09-29 | 4K | 20K | 19.0% | 7 |
| 2026-09-28 | 2K | 13K | 16.5% | 0 |
| 2026-09-25 | 29K | 35K | 83.4% | 0 |
| 2026-09-24 | 1K | 13K | 11.1% | 0 |
| 2026-09-23 | 8K | 51K | 16.4% | 0 |
| 2026-09-22 | 3K | 61K | 5.3% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 24 August 2026, the fails-to-deliver balance in LSTA is 18,139 shares, up 16,920 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (13 August 2025) to 24,477 shares (11 June 2026).
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-24 | 18,139 | $1.55 | $28K |
| 2026-07-29 | 1,219 | $1.16 | $1K |
| 2026-07-28 | 85 | $1.44 | $122 |
| 2026-07-27 | 85 | $1.67 | $142 |
| 2026-07-24 | 10,866 | $2.12 | $23K |
| 2026-07-23 | 10,809 | $2.20 | $24K |
| 2026-06-11 | 24,477 | $3.61 | $88K |
| 2026-05-28 | 27 | $3.30 | $89 |
| 2026-05-18 | 102 | $3.17 | $323 |
| 2026-05-15 | 296 | $3.08 | $912 |
| 2026-05-11 | 55 | $3.15 | $173 |
| 2026-03-25 | 1 | $5.02 | $5 |
| 2026-03-11 | 350 | $5.03 | $2K |
| 2026-02-12 | 743 | $4.54 | $3K |
| 2026-01-29 | 156 | $4.58 | $714 |
| 2026-01-28 | 157 | $4.57 | $717 |
| 2026-01-22 | 245 | $4.03 | $987 |
| 2025-12-26 | 9 | $2.05 | $18 |
| 2025-11-07 | 6 | $2.35 | $14 |
| 2025-11-06 | 6 | $2.34 | $14 |
| 2025-10-31 | 226 | $2.67 | $603 |
| 2025-10-09 | 2,394 | $2.53 | $6K |
| 2025-09-30 | 1,276 | $2.53 | $3K |
| 2025-09-11 | 7,584 | $2.29 | $17K |
| 2025-08-13 | 1 | $2.68 | $3 |
| 2025-08-08 | 3,898 | $2.80 | $11K |
| 2025-07-28 | 100 | $2.69 | $269 |
| 2025-07-25 | 221 | $2.66 | $588 |
| 2025-07-24 | 1,399 | $2.65 | $4K |
| 2025-07-23 | 1,330 | $2.64 | $4K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for LSTA in the last 90 days. The most recent filings are listed below. Latest filing: Nisco James (SVP, Fin/Treas, Chief Actg Off) on 2026-01-09.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-01-09 | Nisco James | SVP, Fin/Treas, Chief Actg Off | Tax withholding | 2K | $1.97 | $4K | 34K |
| 2026-01-09 | Buck Kristen K | EVP, R&D and CMO | Tax withholding | 3K | $1.97 | $6K | 99K |
| 2026-01-09 | Nisco James | SVP, Fin/Treas, Chief Actg Off | Tax withholding | 781 | $1.97 | $2K | 32K |
| 2026-01-09 | Nisco James | SVP, Fin/Treas, Chief Actg Off | Tax withholding | 1K | $1.97 | $2K | 33K |
| 2026-01-09 | Nisco James | SVP, Fin/Treas, Chief Actg Off | Tax withholding | 2K | $1.97 | $4K | 36K |
| 2026-01-09 | Nisco James | SVP, Fin/Treas, Chief Actg Off | Grant | 15K | $0.00 | $0 | 38K |
| 2026-01-09 | Mazzo David J | President & CEO | Tax withholding | 8K | $1.97 | $15K | 312K |
| 2026-01-09 | Mazzo David J | President & CEO | Tax withholding | 12K | $1.97 | $24K | 320K |
| 2026-01-09 | Mazzo David J | President & CEO | Tax withholding | 11K | $1.97 | $21K | 332K |
| 2026-01-09 | Mazzo David J | President & CEO | Tax withholding | 11K | $1.97 | $21K | 342K |
| 2026-01-09 | Mazzo David J | President & CEO | Grant | 81K | $0.00 | $0 | 353K |
| 2026-01-09 | KLOSK STEVEN M | Director | Grant | 30K | $0.00 | $0 | 96K |
| 2026-01-09 | Imam Tariq | SVP, Bus Dev, General Counsel | Tax withholding | 513 | $1.97 | $1K | 36K |
| 2026-01-09 | Imam Tariq | SVP, Bus Dev, General Counsel | Tax withholding | 747 | $1.97 | $1K | 37K |
| 2026-01-09 | Imam Tariq | SVP, Bus Dev, General Counsel | Tax withholding | 840 | $1.97 | $2K | 37K |
| 2026-01-09 | Imam Tariq | SVP, Bus Dev, General Counsel | Tax withholding | 1K | $1.97 | $3K | 38K |
| 2026-01-09 | Imam Tariq | SVP, Bus Dev, General Counsel | Grant | 15K | $0.00 | $0 | 40K |
| 2026-01-09 | HENSON HEIDI | Director | Grant | 30K | $0.00 | $0 | 86K |
| 2026-01-09 | Flowers Cynthia Louise | Director | Grant | 30K | $0.00 | $0 | 95K |
| 2026-01-09 | Buck Kristen K | EVP, R&D and CMO | Tax withholding | 2K | $1.97 | $4K | 93K |
| 2026-01-09 | Buck Kristen K | EVP, R&D and CMO | Tax withholding | 3K | $1.97 | $6K | 96K |
| 2026-01-09 | Buck Kristen K | EVP, R&D and CMO | Tax withholding | 3K | $1.97 | $6K | 102K |
| 2026-01-09 | Buck Kristen K | EVP, R&D and CMO | Grant | 25K | $0.00 | $0 | 105K |
| 2026-01-09 | BROWN GREGORY B | Director | Grant | 30K | $0.00 | $0 | 96K |
| 2026-01-09 | AZAB MOHAMMAD | Director | Grant | 30K | $0.00 | $0 | 105K |
| 2025-01-10 | Mazzo David J | President & CEO | Tax withholding | 3K | $3.73 | $12K | 265K |
| 2025-01-10 | Buck Kristen K | EVP, R&D and CMO | Tax withholding | 456 | $3.73 | $2K | 80K |
| 2025-01-10 | Nisco James | SVP, Fin/Treas, Chief Actg Off | Tax withholding | 416 | $3.73 | $2K | 23K |
| 2025-01-09 | AZAB MOHAMMAD | Director | Grant | 16K | $0.00 | $0 | 74K |
| 2025-01-09 | Flowers Cynthia Louise | Director | Grant | 16K | $0.00 | $0 | 65K |
| 2025-01-09 | HENSON HEIDI | Director | Grant | 16K | $0.00 | $0 | 55K |
| 2025-01-09 | BROWN GREGORY B | Director | Grant | 16K | $0.00 | $0 | 65K |
| 2025-01-09 | KLOSK STEVEN M | Director | Grant | 16K | $0.00 | $0 | 65K |
| 2025-01-09 | Mazzo David J | President & CEO | Tax withholding | 9K | $3.80 | $36K | 286K |
| 2025-01-09 | Mazzo David J | President & CEO | Tax withholding | 11K | $3.80 | $42K | 275K |
| 2025-01-09 | Mazzo David J | President & CEO | Tax withholding | 7K | $3.80 | $27K | 268K |
| 2025-01-09 | Mazzo David J | President & CEO | Grant | 81K | $0.00 | $0 | 295K |
| 2025-01-09 | Buck Kristen K | EVP, R&D and CMO | Tax withholding | 3K | $3.80 | $11K | 82K |
| 2025-01-09 | Buck Kristen K | EVP, R&D and CMO | Tax withholding | 2K | $3.80 | $7K | 80K |
| 2025-01-09 | Buck Kristen K | EVP, R&D and CMO | Grant | 25K | $0.00 | $0 | 88K |
| 2025-01-09 | Buck Kristen K | EVP, R&D and CMO | Tax withholding | 3K | $3.80 | $10K | 85K |
| 2025-01-09 | Nisco James | SVP, Fin/Treas, Chief Actg Off | Tax withholding | 1K | $3.80 | $4K | 25K |
| 2025-01-09 | Nisco James | SVP, Fin/Treas, Chief Actg Off | Tax withholding | 781 | $3.80 | $3K | 24K |
| 2025-01-09 | Nisco James | SVP, Fin/Treas, Chief Actg Off | Tax withholding | 2K | $3.80 | $8K | 26K |
| 2025-01-09 | Nisco James | SVP, Fin/Treas, Chief Actg Off | Grant | 15K | $0.00 | $0 | 28K |
| 2024-10-01 | Mazzo David J | President & CEO | Tax withholding | 27K | $2.93 | $79K | 212K |
| 2024-10-01 | Mazzo David J | President & CEO | Grant | 58K | $2.93 | $170K | 239K |
| 2024-10-01 | Nisco James | SVP, Fin/Treas, Chief Actg Off | Grant | 3K | $2.93 | $10K | 15K |
| 2024-10-01 | Nisco James | SVP, Fin/Treas, Chief Actg Off | Tax withholding | 2K | $2.93 | $5K | 13K |
| 2024-10-01 | Buck Kristen K | EVP, R&D and CMO | Grant | 15K | $2.93 | $44K | 69K |
| 2024-10-01 | Buck Kristen K | EVP, R&D and CMO | Tax withholding | 6K | $2.93 | $19K | 63K |
| 2024-01-11 | Mazzo David J | Chief Executive Officer | Tax withholding | 1K | $2.99 | $3K | 175K |
| 2024-01-10 | Mazzo David J | Chief Executive Officer | Tax withholding | 3K | $3.00 | $10K | 176K |
| 2024-01-10 | Buck Kristen K | EVP, R&D and CMO | Tax withholding | 512 | $3.00 | $2K | 54K |
| 2024-01-09 | AZAB MOHAMMAD | Director | Grant | 19K | $0.00 | $0 | 59K |
| 2024-01-09 | BROWN GREGORY B | Director | Grant | 19K | $0.00 | $0 | 49K |
| 2024-01-09 | Flowers Cynthia Louise | Director | Grant | 19K | $0.00 | $0 | 49K |
| 2024-01-09 | HENSON HEIDI | Director | Grant | 19K | $0.00 | $0 | 39K |
| 2024-01-09 | KLOSK STEVEN M | Director | Grant | 19K | $0.00 | $0 | 50K |
| 2024-01-09 | Mazzo David J | Chief Executive Officer | Tax withholding | 12K | $3.08 | $38K | 187K |
| 2024-01-09 | Mazzo David J | Chief Executive Officer | Tax withholding | 8K | $3.08 | $24K | 179K |
| 2024-01-09 | Mazzo David J | Chief Executive Officer | Grant | 94K | $0.00 | $0 | 199K |
| 2024-01-09 | Buck Kristen K | EVP, R&D and CMO | Tax withholding | 2K | $3.08 | $7K | 55K |
| 2024-01-09 | Buck Kristen K | EVP, R&D and CMO | Grant | 27K | $0.00 | $0 | 60K |
| 2024-01-09 | Buck Kristen K | EVP, R&D and CMO | Tax withholding | 3K | $3.08 | $10K | 57K |
| 2023-09-01 | Buck Kristen K | EVP, R&D and CMO | Tax withholding | 3K | $2.18 | $6K | 33K |
| 2023-01-13 | Mazzo David J | Chief Executive Officer | Tax withholding | 397 | $3.65 | $1K | 97K |
| 2023-01-11 | Mazzo David J | Chief Executive Officer | Tax withholding | 1K | $3.20 | $3K | 97K |
| 2023-01-10 | Buck Kristen K | EVP, R&D and CMO | Tax withholding | 512 | $3.20 | $2K | 36K |
| 2023-01-10 | Mazzo David J | Chief Executive Officer | Tax withholding | 3K | $3.20 | $11K | 98K |
| 2023-01-09 | Buck Kristen K | EVP, R&D and CMO | Tax withholding | 2K | $3.00 | $6K | 36K |
| 2023-01-09 | Buck Kristen K | EVP, R&D and CMO | Grant | 18K | $0.00 | $0 | 38K |
| 2023-01-09 | Mazzo David J | Chief Executive Officer | Grant | 60K | $0.00 | $0 | 109K |
| 2023-01-09 | Mazzo David J | Chief Executive Officer | Tax withholding | 8K | $3.00 | $24K | 101K |
| 2023-01-09 | Slack David W. | President & CBO | Grant | 24K | $0.00 | $0 | 24K |
| 2023-01-09 | Slack David W. | President & CBO | Tax withholding | 3K | $3.00 | $10K | 21K |
| 2023-01-09 | AZAB MOHAMMAD | Director | Grant | 20K | $0.00 | $0 | 39K |
| 2023-01-09 | BROWN GREGORY B | Director | Grant | 20K | $0.00 | $0 | 30K |
| 2023-01-09 | Flowers Cynthia Louise | Director | Grant | 20K | $0.00 | $0 | 30K |
| 2023-01-09 | HENSON HEIDI | Director | Grant | 20K | $0.00 | $0 | 20K |
| 2023-01-09 | KLOSK STEVEN M | Director | Grant | 20K | $0.00 | $0 | 30K |
| 2023-01-09 | Ruoslahti Erkki | Director | Grant | 20K | $0.00 | $0 | 20K |
| 2022-09-15 | AZAB MOHAMMAD | Director | Grant | 19K | $6.25 | $120K | 19K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON1 holder reports 5% or more of LSTA in its latest filing, on Schedule 13G (passive). The holder is Branham Justin Earl at 5.1% of the class (462,149 shares), filed 2026-08-26 for an event on 2026-08-21.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-26 | 13G | Branham Justin Earlindividual | 462K | 5.1% | 2026-08-21 |
13F holders
Tracked managers holding LSTA at their latest 13F. JSON1 of the 30 tracked managers held LSTA at their latest 13F, $53K in total at quarter-end prices. Citadel Advisors is the largest at $53K (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 0 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Citadel Advisors | 2026-06-30 | 16K | $53K | 0.00% | -7K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Lisata Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Lisata Therapeutics (LSTA), SEC CIK 320017, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-08-24.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-26.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2025-11-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-01-09.JSON and CSV
- Company record
- EDGAR filing index for CIK 320017Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of LSTA is sold short?
What is LSTA's daily short volume?
Does LSTA have fails to deliver?
Are LSTA insiders buying or selling?
Who owns 5% or more of LSTA?
Which tracked 13F managers own LSTA?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.